Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Metal & realty in limelight
Mon, 29 Dec 01:30 pm

Indian share markets continued to remain buoyant in the post-noon trading session. All the sectoral indices are trading in the green. Metal and realty stocks are the biggest gainers today.

BSE-Sensex is up 180 points and NSE-Nifty is trading 52 points up. BSE Mid Cap is trading 0.9% up and BSE Small Cap index is trading up by 0.7%. The rupee is trading at 63.61 to the US dollar.

Majority of the engineering stocks are trading firm led by Everest Kanto Cylinder and Jindal Drilling. As per a leading financial daily, Larsen & Toubro's (L&T's) subsidiary L&T Hydrocarbon Engineering has won an offshore contract worth Rs 8.9 bn from Oil & Natural Gas Corporation (ONGC). The contract is for the additional development of the Vasai East project to improve its recovery rate. The Vasai East project had commenced production in 2008. The project is expected to be completed by April 2016. L&T stock is presently trading up 0.7%.

Most of the domestic pharma stocks are trading in the green with Ranbaxy laboratories and Lupin being the biggest gainers. As per a leading financial daily, Lupin is on the look-out for acquisitions in markets of US, Europe (Russia, Turkey), Latin America, Japan and China to widen its overseas presence. The company is eyeing suitable acquisitions in the inhalation, complex injectables and derma space. In FY14, international operations formed 75% of the overall revenues for the company out of which the US markets alone accounted for a lion's share of 44%. The company expects the US generics business to remain a principal growth driver with 15-20 generic product launches lined up over the next 12-15 months. Lupin presently has 200 abbreviated new drug applications (ANDA) filings with US Food & Drug Administration (USFDA) out of which 100 are pending approvals and 30 are exclusive first to file. The company has also signed various agreements in the US market in FY14. The company expects its third largest business in Japan to grow by 15-20% in future.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Metal & realty in limelight". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Feb 21, 2018 (Close)